Ph.D., CEO, Kiromic Biopharma Inc.
Maurizio Chiriva-Internati PhD is the Chairman, CEO and CSO of Kiromic Biopharma Inc (Houston Texas, www.kiromic.com). For the past 20 years he has successfully built and led pharmaceutical drug management and tumor specific antigen research and development teams commercializing therapeutic drug and companion diagnostic product candidates. Maurizio and his teams identified novel cancer testis antigens and other antigen epitopes (including high value human cancer Kirotopes™) enabling development and commercialization of safe and effective immunotherapeutics and diagnostics against metastatic solid or liquid human tumors. Dr. Chiriva-Internati has developed high value new therapeutic product candidates for multiple myeloma, acute myeloid leukemia, ovarian, lung, prostate, melanoma, and breast cancer patients. He is also an internationally recognized author of over 150 peer-reviewed publications and a senior reviewer for many neoantigen programs and scientific journal publications, including The Lancet Infectious Diseases, Cancer Research, The Journal of Immunology, International Reviews of Immunology, and Nature Reviews Clinical Oncology.